IS:PEL Piramal Enterprises Limited

Piramal Enterprises Limited primarily manufactures and sells pharmaceutical, medicinal, and chemical and botanical products in India and internationally. It operates through Pharmaceuticals Manufacturing and Services, Financial Services, and Information Management segments. The company provides pharmaceuticals development and manufacturing services throughout the drug lifecycle, as well as offers specialized services, such as antibody drug conjugation. It also manufactures and sells inhalation anaesthetics, including Halothane, Isoflurane, and Sevoflurane; critical care products, such as Propofol; and plasma volume expanders comprising Polygeline. In addition, the company offers vitamins and nutrition, analgesics, dermatological products, and antacids; and a product portfolio of molecular imaging probes that address clinical needs in oncology, neurodegenerative, and cardiovascular diseases. Further, it provides florbetaben, an 18F-labeled tracer used in positron emission tomography; and a range of PhytoMedicines products to manage lifestyle ailments, such as diabetes, arthritis, obesity, constipation, liver damage, anxiety, sexual dysfunction, cough and cold, etc. Additionally, the company offers finance to real estate developers; structured mezzanine funding to corporates in various sectors, including infrastructure; and data and analytics, research reports, and knowledge-based services to pharmaceutical, biotech, medical device, financial services, and managed care industries, as well as engages in NBFC operations. Piramal Enterprises Limited has strategic alliances with CPPIB Credit Investment Inc., and APG Asset Management and Bain Capital Credit. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is headquartered in Mumbai, India.

2,527.85 INR
As of 01/21/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Financials
Industry:  Drug Manufacturers-Specialty &
Index country:  India
Country of incorporation:  India
IPO date:  12/31/1999
Stock exchange:    National Stock Exchange O
Exchange country:   India
Market cap:   603,306,786,816 INR
Current dividend yield:   1.28%
Sedol:      B058J56

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy